Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, representing approximately 40% of all pediatric soft tissue sarcomas and 3% of all pediatric cancers. RMSs are a heterogeneous group of neoplasms with variations in morphology, molecular characteristics, and outcomes. Due to this diversity, the landscape of knowledge on these tumors is continuously evolving with a broad range of ongoing research into molecular characterization, prognostication, and potential targeted-treatment modalities. Herein, we review the current classification schema and incorporate new information, expanding the understanding of RMS.